Boston Biomedical has named Pfizer veteran Patricia Andrews as chief commercial officer.
Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic colorectal cancer.
She previously spent 17 years at Pfizer, rising to VP and general manager of US oncology, before joining from oncology/inflammation-focused Incyte Corporation where she served as executive VP and chief commercial officer.
At Incyte, she established the company’s commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.
Andrews is expected to perform a similar role at Boston, which has so far been focused on research.
“I am very excited about this opportunity and look forward to building a world-class commercial oncology team at Boston Biomedical,” she said.